Biosimilars
A new kind of drug that could save the US billions is finally starting to gain traction — here are the companies that have the most to gain
BI PRIME: Analysts at Credit Suisse are starting to get more optimistic on biosimilars, saying the drugs are about to "make their mark." That's in part because of attention placed on biosimilars by regulators and politicians — and doctors who are becoming more comfortable prescribing them.
The FDA just approved the first direct competitor to a $6.7-billion-dollar cancer drug
The FDA approved a version of Herceptin, a blockbuster drug used to treat breast and stomach cancer made by Genentech that made $6.7 billion in sales in 2016.
Pfizer is taking its fight with J&J over a blockbuster drug to court
Pfizer filed a complaint against J&J, claiming it was taking anticompetitive steps to block the sale of Inflectra, Pfizer's biosimilar to Remicade.
The FDA just approved the first direct competitor to a billion-dollar cancer drug
The newly approved drug, made by Amgen, will go by the marketed name Mvasi. It's a type of medication called a "biosimilar."
New drugs could save the US billions of dollars — but there's something holding them back
Biosimilars have had a disappointing start, but there are a few companies that are shaping up to do well.
Advertisement
Advertisement
A cheaper version of the lifesaving diabetes medication just launched in the US
A pack of 5 pens of Basaglar has a list price of $316.85 — that's before any discounts, or factoring in what insurance might cover.
A cheaper version of a best-selling rheumatoid arthritis drug will be here in November — and it’s just the start
Pfizer Inc said on Monday it will begin shipping its biosimilar version of the rheumatoid arthritis drug Remicade in late November at a 15% discount.
The FDA just approved another new drug that could save the US billions — but there's a catch
The drug, called Amjevita (adalimumab-atto), is a "biosimilar," which is like a generic version of a biologic medication, a medicine produced by living cells.
The potential for biosimilars is huge
Most of the major players in biosimilars are large, diversified multinationals that are somewhat insulated against a possible bust.
A new drug that could save the US billions just got approved
An approved biosimilar of the blockbuster drug Enbrel could change the way biosimilars are used.
CVS just made a move that could help customers save billions on prescription drugs
CVS announced on Tuesday that in 2017 it would no longer supply two branded drugs in favor of their copycat versions, called biosimilars.
A new drug that could save the US billions just got one step closer to an approval
An approved biosimilar of the blockbuster drug Humira could change the way biosimilars are used.
A Russian drug company is accusing Roche of sabotaging biosimilar competition
Biocad is accusing Roche of deliberately setting low prices in Russia and using other allegedly illegal tactics to sabotage biosimilar competition.
New drugs that could save the US billions just got an approval that will change the face of Big Pharma
The second biosimilar is a big deal for companies trying to make other biosimilars.
A new drug that could save the US billions of dollars just got approved
The drug, developed by Celltrion and which will be co-marketed by Pfizer, goes by the name "Inflectra."
Advertisement
Advertisement
A new class of drugs could save the US billions of dollars – but we’re way behind in adopting them
Biosimilars could save the US billions in drug costs. But will we use them?
A new drug that could save the US billions of dollars just got one step closer to approval
Biosimilars could be the force biotech companies need to keep innovating.
There's a new type of medicine that could save the US billions over the next decade — but not everyone wants that to happen
Biosimilars could be the force biotech companies need to keep innovating.